Plus Therapeutics Inc. (NASDAQ:PSTV) jumped 60% in premarket trading Thursday following news of a national agreement with UnitedHealthcare Insurance Company (NYSE:UNH) covering its CNSide® Cerebrospinal Fluid Tumor Cell Enumeration test.
The agreement, effective September 15, 2025, provides coverage for more than 51 million people across the United States. The test is available through CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics.
The CNSide® CSF Assay Platform supports rapid diagnosis, treatment monitoring, and therapeutic guidance for patients with leptomeningeal metastases. The company states that the test has shown superior clinical utility over standard-of-care methods in nine peer-reviewed publications and the FORESEE clinical trial.
Since 2020, over 11,000 CNSide® tests have been conducted at more than 120 U.S. cancer centers. The company reports the test demonstrates 92% sensitivity and 95% specificity, while impacting treatment decisions in 90% of cases.
The assay is offered exclusively through CNSide Diagnostics as a service for healthcare professionals in the United States.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.